Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016

Lugli, Alessandro; Kirsch, Richard; Ajioka, Yoichi; Bosman, F.; Cathomas, Gieri; Dawson, Heather; Zimaity, Hala El; Fléjou, Jean François; Hansen, Tine Plato; Hartmann, Arndt; Kakar, Sanjay; Langner, Cord; Nagtegaal, Irıs D.; Puppa, Giacomo; Riddell, Robert H.; Ristimäki, Ari; Sheahan, Kieran; Smyrk, Thomas C.; Sugihara, Kenichi; Terris, Benoı̂t; Ueno, Hideki; Vieth, Michael; Zlobec, Inti; Quirke, Philip

doi:10.1038/modpathol.2017.46

Cited by 802 publications

(1,066 citation statements)

References 87 publications

Supporting

Mentioning

924

Contrasting

Unclassified

Order By: Relevance

“…2,8,9,11,12,20,27,34,40,45,48,54 This definition is in accordance with the recent recommendation by the International Tumor Budding Consensus Conference (ITBCC 2016) in colorectal cancer, 55 and also agrees with studies on other cancers. 2,8,9,11,12,20,27,34,40,45,48,54 This definition is in accordance with the recent recommendation by the International Tumor Budding Consensus Conference (ITBCC 2016) in colorectal cancer, 55 and also agrees with studies on other cancers.…”

Section: Evaluation Of Tumor Buddingsupporting

confidence: 87%

Hallmarks of cancer: Tumor budding as a sign of invasion and metastasis in head and neck cancer

et al. 2019

View full text Add to dashboard Cite

Invasion and metastasis are hallmarks of cancer. The concept of tumor budding at tumor‐host interface has been documented in many carcinomas. A growing body of evidence indicates that tumor budding is a sign of invasion and early step for metastasis of many epithelial cancers including head and neck squamous cell carcinoma (HNSCC). In addition, recent research has underlined the importance of tumor budding as a promising prognosticator in HNSCC. This review summarizes the findings regarding tumor budding in HNSCC and focuses on the role of tumor budding in invasion and metastasis. Also, we highlight the prognostic significance of tumor budding in HNSCC and its potential for improving clinical decision making in terms of recommending optimal individualized treatment for this patient population.

show abstract

Section: Evaluation Of Tumor Buddingsupporting

confidence: 87%

Hallmarks of cancer: Tumor budding as a sign of invasion and metastasis in head and neck cancer

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Tumour budding is considered to be a good marker for progression and prognosis and has potential clinical implications in colorectal carcinomas . The International Tumour Budding Consensus Conference (ITBCC) recommended including tumour budding into future colorectal cancer guidelines . The obstacle of different assessment criteria has been overcome, but the significance of reliability in daily practice has to be clarified further .…”

Section: Introductionmentioning

confidence: 99%

Level of interobserver variability estimation as a valuable tool: assessment of tumour budding in colon cancer

et al. 2018

View full text Add to dashboard Cite

show abstract

“…By counting multiple fields, this method has the advantage of assessing the heterogeneity observed in tumor budding and there is evidence of a high interobserver correlation. However, in 2016, the International Tumour Budding Consensus Conference recommended the use of the “hotspot method” for tumor budding assessment [27]. In this method, tumor bud counts are performed in a single HPF with the highest density of tumor buds.…”

Section: Intertumor Heterogeneitymentioning

confidence: 99%

Tumor Heterogeneity in Colorectal Cancer: What Do We Know So Far?

Sagaert¹,

Vanstapel²,

Verbeek³

2018

Pathobiology

138

View full text Add to dashboard Cite

Colorectal cancer is not one disease but rather a collection of neoplastic diseases. Due to heterogeneity in the disease biology, therapy response, and prognosis, extensive disease stratification is required. Therefore, TNM stage, microsatellite status, tumor grade, lymphovascular invasion, and other parameters are assessed in the pathology report to indicate the extent and prognosis of the disease. The mutation status of KRAS, BRAF, and NRAS is also investigated in a metastatic context to predict the response to anti-EGFR therapy. Recently, 4 distinct molecular subtypes of colorectal cancer have been described that have both prognostic and therapeutic relevance. In addition, characterization of the inflammatory infiltrate revealed major differences in the amount and location of inflammatory cells in distinct colorectal tumor types. Together, all of these parameters help to stratify patients into different therapeutic and prognostic subgroups. However, this stratification is not unambiguous since tumors often display intratumoral heterogeneity, whereby several subpopulations within one tumor show differences in morphology, inflammatory infiltrate, mutational status, or gene expression profile. This article gives an overview of all of the current known data with regard to tumor heterogeneity at both inter- and intratumoral levels.

show abstract

Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016

Cited by 802 publications

References 87 publications

Hallmarks of cancer: Tumor budding as a sign of invasion and metastasis in head and neck cancer

Hallmarks of cancer: Tumor budding as a sign of invasion and metastasis in head and neck cancer

Level of interobserver variability estimation as a valuable tool: assessment of tumour budding in colon cancer

Tumor Heterogeneity in Colorectal Cancer: What Do We Know So Far?

Contact Info

Product

Resources

About